XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies (Details Narrative) - USD ($)
 6 Months Ended
Feb. 05, 2024
Nov. 03, 2020
Jun. 30, 2024
Payments For Future Research And Collobration     $ 1,343,741
Total Grants Repayable     464,108
Principal balance payable     163,668
Aggerate Amount Payable, Description   under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million  
Loan agreement, Description 9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024    
Total Long-Term Debt     4,908,499
Amount payable for services rendered     146,221
Amount may be payable by Company in future periods for services rendered     363,778
Accrued compensation expense     536,535
Recognized total compensation expense     335,013
RSU 2023 [Member]      
Unrecognized compensation expense     390,276
RSU 2024 [Member]      
Unrecognized compensation expense     59,290
RSU 2025 [Member]      
Unrecognized compensation expense     150,277
RSU 2026 [Member]      
Unrecognized compensation expense     180,709
Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]      
Collaborative Obligations Amount Due     204,087
Additional Cost Of Company     449,406
Cost     449,406
August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member]      
Collaborative Obligations Amount Due     0
Additional Cost Of Company     164,235
Cost     164,235
July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]      
Collaborative Obligations Amount Due     26,142
Additional Cost Of Company     81,447
Cost     107,589
January TwoThousand Twenty Four [Member] | University Medical Centre Amsterdam[Member]      
Collaborative Obligations Amount Due     46,218
Additional Cost Of Company     138,653
Cost     138,653
Managing Director's Agreement [Member]      
Amount payable     209
Royalty Payment     117,761
Clinical Study Research Agreement [Member] | In 2018 [Member] | University of Taiwan [Member]      
Collaborative Obligations Amount Due     510,000
Collaborative Obligations Amount     $ 25,500
Lease Agreement Expire Period     three-year
Restricted Stock Units (RSUs) [Member]      
Recognized total compensation expense     $ 1,291,594
RSU Vested in 2024     451,490
RSU Vested in 2023     527,940
RSU Vested in 2025     312,164
Unrecognized compensation expense     282,823
Operating Lease Right of Use Obligations [Member]      
Payment Of Lease Liabilities     125,313
Operating Lease Expense     126,217
Short Term Lease Costs     $ 40,334